Departamento de Coordinación de Garantías y Prestaciones de Salud, División de Planificación Sanitaria, Ministerio de Salud de Chile, Enrique McIver 421, Santiago, Chile.
Centro de Investigación Clínica, Unidad de Evaluación de Tecnologías en Salud (ETESA UC), Pontificia Universidad Católica de Chile, Santiago, Chile.
Orphanet J Rare Dis. 2024 Jun 24;19(1):243. doi: 10.1186/s13023-024-03249-z.
To review the available evidence about the strategies implemented or proposed for coverage or reimbursement for currently approved gene therapies.
A scoping review was conducted to analyze the evidence published during the years 2016 to 2023. The main search criteria were coverage or reimbursement of gene therapy by healthcare systems. The eligible articles were those that described or proposed a financing model used to provide coverage in the various systems around the world.
The study identified 279 publications, and after removing duplicates and screening for eligibility, 10 were included in the study. The results show that various financing models have been proposed, including subscription-based payment models, outcome-based payment models, and amortization strategies. However, several barriers to implementing these models were identified, such as deficiencies in informatics systems for data collection, changes in laws or regulations, the lack of accessible clinical endpoints and administrative costs.
This scoping review provides an overview of financing strategies for gene therapies. Gene therapies can cure rare or previously intractable diseases, but their high cost can make access difficult. Publishing experiences with these models can help evaluate their use and gather more evidence for their effectiveness.
回顾目前已批准的基因治疗药物的覆盖范围或报销所实施或提出的策略的现有证据。
进行了范围界定审查,以分析 2016 年至 2023 年期间发表的证据。主要搜索标准是医疗保健系统对基因治疗的覆盖范围或报销。合格的文章是那些描述或提出用于在世界各地的各种系统中提供覆盖范围的融资模式的文章。
研究确定了 279 篇出版物,在去除重复项并进行资格筛选后,有 10 篇被纳入研究。结果表明,已经提出了各种融资模式,包括基于订阅的支付模式、基于结果的支付模式和摊销策略。然而,确定了实施这些模型的几个障碍,例如数据收集信息系统的缺陷、法律或法规的变化、缺乏可及的临床终点和行政成本。
本范围界定审查提供了基因治疗融资策略的概述。基因疗法可以治愈罕见或以前难以治疗的疾病,但它们的高成本可能使其难以获得。发表这些模型的经验可以帮助评估它们的使用,并为它们的有效性收集更多证据。